top of page
LATEST NEWS
What RMAT Designation Actually Means for a Gene Therapy
RMAT shows up in headline after headline. Here is what the FDA designation requires, what it gives developers, and the one thing it does not mean.
3 hours ago3 min read


FDA Grants RMAT to Kamau's Sickle Cell Therapy That Corrects the Mutation Itself
Nula-cel repairs the sickle mutation in a patient's own stem cells rather than switching on fetal hemoglobin. All three patients on the optimized process are transfusion-free with no pain crises.
1 day ago3 min read


A Cancer-Killing Virus Cut Bladder Cancer Recurrence by 68% in a Phase 3 Trial
CG Oncology's cretostimogene reduced the risk of recurrence by 68% versus surveillance in 367 patients with intermediate-risk bladder cancer, with no serious treatment-related side effects.
2 days ago3 min read


LEARN MORE
LEARN MORE

GENE TECH TIMES
The Future Has Arrived


FDA Approves Otarmeni, the First Gene Therapy for Genetic Hearing Loss
Regeneron's Otarmeni became the first FDA-approved gene therapy for hearing loss and the first dual-AAV therapy, approved in a record 61 days. Here's how it restores hearing in OTOF deafness.
Apr 22
bottom of page


